Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Graybug Vision, a clinical-stage biopharmaceutical company focused on retinal and optic nerve diseases, announced that CEO Fred Guerard will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Graybug Vision, a clinical-stage biopharmaceutical company focused on retinal and optic nerve diseases, announced that CEO Fred Guerard will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The chat will be available on November 22, 2021, at 10 a.m. ET. Investors can also schedule 1x1 meetings through Piper Sandler. Graybug's lead candidate, GB-102, targets retinal diseases with a six-month or longer dosing regimen, while GB-401 is aimed at glaucoma treatments. For more details, visit Graybug's website.
Details
News Market Reaction – GRAY
The recorded move for GRAY in the trading session of this news was -4.98%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a pre-recorded fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference, which will be available on the conference website beginning at 10 a.m. ET / 7 a.m. PT on November 22, 2021.
A link to the fireside chat will also become available at the same time in the Investors and Media section of the company’s website at https://investors.graybug.vision/news-events/events-presentations.
Graybug will be participating in 1x1 meetings with investors during the conference, and meetings can be requested exclusively via Piper Sandler.
About Graybug
Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company’s proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for six months and potentially longer, improving disease management, reducing healthcare burdens and ultimately delivering better clinical outcomes. Graybug’s lead product candidate, GB-102, a formulation of the pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib malate targeting a six-month or longer dosing regimen, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including wet age-related macular degeneration. Graybug’s other product candidates developed using its proprietary technologies also include GB-401, an injectable sustained-release formulation of a beta-adrenergic blocker prodrug, for primary open-angle glaucoma, with a dosing regimen of once every six months or longer. Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, the company has offices in Baltimore, Maryland, and Redwood City, California. For more information, please visit www.graybug.vision.
| Investor Contact IR@graybug.vision (650) 487-2409 | Media Contact media@graybug.vision (404) 384-0067 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.